Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

J Clin Oncol. 2024 Apr 30:JCO2400711. doi: 10.1200/JCO.24.00711. Online ahead of print.NO ABSTRACTPMID:38687953 | DOI:10.1200/JCO.24.00711
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Source Type: research